Equitable access to safe and effective vaccines is vital to eliminating the COVID-19 pandemic, so seeing so many vaccines in testing and development is quite encouraging. Safe and efficient vaccines are a game-changing weapon, but for the time being, we must continue to wear masks, wash our hands, ensure proper ventilation indoors, and physically distance ourselves from and avoid crowds. Being vaccinated does not allow us to disregard caution and endanger ourselves and others, especially when research into how well vaccines protect not only against sickness but also against infection and transmission is underway. But it is vaccination, not vaccines, that will put an end to the epidemic. We must assure fair and equitable access to vaccines, as well as that every country obtains them and can use them to safeguard its citizens, beginning with the most vulnerable.
The COVID-19 vaccine created by the US pharmaceutical giant Pfizer and Germany's BioNTech was the first COVID-19 vaccine licensed for emergency use by the US FDA.The vaccine developed by Pfizer and BioNTech employs messenger RNA (mRNA) technology. mRNA vaccines instruct our cells to produce a protein that causes an immunological response within our bodies. This is in contrast to standard immunizations, which introduce weakened or inactivated germs into our bodies. Pfizer-BioNTech's COVID-19 vaccines need to be kept at minus 70 degrees Celsius, which presents logistical challenges, especially for poorer countries. The United Kingdom was the first country in the globe to begin administering shots on December 8, with the United States following a week later on December 16. The Pfizer-BioNTech COVID-19 vaccine has also been approved for use in Malaysia, Singapore, Canada, Mexico, and Saudi Arabia.
The CoronaVac vaccine, developed by China's Sinovac Biotech, is currently undergoing phase 3 clinical trials in countries such as Brazil and Indonesia. Sinovac's vaccine use inactivated vaccine technology, which employs deceased virus particles to drive human bodies' immunological responses. This vaccination works in the same way as the flu vaccine. The vaccination can be kept in a regular refrigerator at temperatures ranging from 2 to 8 degrees Celsius for up to three years. This could be an appealing solution in areas where access to refrigeration is limited.
The AstraZeneca COVID-19 vaccine, currently known as Vaxzevria, is a viral vector vaccine, similar to the Johnson & Johnson vaccine. To elicit an immune response, the vaccine employs a chimp adenovirus to transport spike proteins from the coronavirus into your bloodstream. It can be manufactured on a big scale and at a low cost, which is essential during a pandemic. Unlike Pfizer and Moderna vaccines, it can also be stored in a standard refrigerator. Despite initial concerns regarding its safety with blood clots, the European Medicines Agency (EMA) has deemed it safe, and the World Health Organization (WHO)continues to recommend it.
The section for vaccine registration is now available on the MySejahtera app - make sure your app is updated to the latest version on the App Store or Google Play.
Once you've updated your app, relaunch the MySejahtera app and you should be able to see a ‘COVID-19 Vaccination’ button on the home screen. Tap on the button and make sure your personal details (name, IC, phone number) are accurate.
Once your details are verified, you’ll be led to this frame. Click on the ‘click here’ link to complete your registration by filling up a form with 4 simple yes/no questions. Once you’ve done so, you’ll be notified when the next phase of vaccination begins (details about the vaccination centre and dates assigned will be sent to you via the MySejahtera App, phone call, or text).
About Me